Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 History  





2 Preparations  





3 Mechanism of action  





4 Synthesis  





5 See also  





6 References  





7 External links  














Cromoglicic acid






العربية
تۆرکجه
Cymraeg
Deutsch
Español
Euskara
فارسی
Français
Gaeilge
Italiano
Magyar
Nederlands

ି
Polski
Português
Русский
Simple English
Српски / srpski
Srpskohrvatski / српскохрватски
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Cromoglicic acid
Clinical data
AHFS/Drugs.comInternational Drug Names
License data
Pregnancy
category
  • AU: B1
  • Routes of
    administration
    topical: oral, nasal spray, inhaled, eye drops
    ATC code
    Legal status
    Legal status
    • AU: S2 (Pharmacy medicine)
  • UK: inhaler POM; eye OTC
  • US: OTC nasal; eye, inhaler: Rx only
  • Pharmacokinetic data
    Bioavailability1%
    Elimination half-life1.3 hours
    Identifiers
    • 5,5′-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-2-carboxylic acid)

    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.036.602 Edit this at Wikidata
    Chemical and physical data
    FormulaC23H16O11
    Molar mass468.370 g·mol−1
    3D model (JSmol)
    • O=C(O)C=4Oc3cccc(OCC(O)COc2cccc1O/C(=C\C(=O)c12)C(=O)O)c3C(=O)C=4

    • InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30) checkY

    • Key:IMZMKUWMOSJXDT-UHFFFAOYSA-N checkY

     ☒NcheckY (what is this?)  (verify)

    Cromoglicic acid (INN)—also referred to as cromolyn (USAN), cromoglycate (former BAN), or cromoglicate—is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicateorcromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells.

    It is considered a breakthrough drug in management of asthma, as the patients can be freed from steroids in many cases; however, it is mainly effective as a prophylaxis for allergic and exercise-induced asthma, not as a treatment for acute asthma attacks.[citation needed]

    Cromoglicic acid has been the non-corticosteroid treatment of choice in the treatment of asthma, for which it has largely been replaced by leukotriene receptor antagonists because of their safety and convenience. Cromoglicic acid requires administration four times daily, and does not provide additive benefit in combination with inhaled corticosteroids.[1]

    History[edit]

    Cromolyn was discovered in 1965 by Roger Altounyan, a pharmacologist who had asthma. Altounyan was investigating certain plants and herbs which have bronchodilating properties. One such plant was khella (Ammi visnaga) which had been used as a muscle relaxant since ancient times in Egypt. Altounyan deliberately inhaled derivatives of the active ingredient khellin to determine if they could block his asthma attacks. After several years of trial, he isolated an effective and safe asthma-preventing compound called cromolyn sodium.[2]

    Preparations[edit]

    Cromoglicic acid is available in multiple forms:

    Mechanism of action[edit]

    "Cromolyn works because it prevents the release of mediators that would normally attract inflammatory cells and because it stabilizes the inflammatory cells. MCT mast cells found in the mucosa are stabilised."[8] Nedocromil is another mast cell stabilizer that also works in controlling asthma. The underlying mechanism of action is not fully understood; for while cromoglicate stabilizes mast cells, this mechanism is probably not why it works in asthma.[9] Pharmaceutical companies have produced 20 related compounds that are equally or more potent at stabilising mast cells and none of them have shown any anti-asthmatic effect.[9] It is more likely that these work by inhibiting the response of sensory C fibers to the irritant capsaicin, inhibiting local axon reflexes involved in asthma, and may inhibit the release of preformed T cell cytokines and mediators involved in asthma.[10]

    It is known to somewhat inhibit chloride channels (37% ± 7%)[11] and thus may inhibit the:

    Note: Another chemical (NPPB: 5-nitro-2(3-phenyl) propylamino-benzoic acid) was shown, in the same study, to be a more effective chloride channel blocker.

    Finally it may act by inhibiting calcium influx.

    Cromoglicate is classified as a chromone.

    Cromolyn is also being tested as a drug to treat insulin-induced lipoatrophy[12][13] and Alzheimer's disease in combination with Ibuprofen.[14] Cromolyn is also known to bind S100P protein and disrupt the interaction with RAGE.[15][16]

    Synthesis[edit]

    Cromoglicic acid synthesis.

    See also[edit]

    Visnaga daucoides

    References[edit]

    1. ^ Fanta CH (March 2009). "Asthma". The New England Journal of Medicine. 360 (10): 1002–1014. doi:10.1056/NEJMra0804579. PMID 19264689. Review.
  • ^ . doi:10.1016/S0954-6111(89)80245-8. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help)
  • ^ Schwartz HJ, Blumenthal M, Brady R, Braun S, Lockey R, Myers D, et al. (April 1996). "A comparative study of the clinical efficacy of nedocromil sodium and placebo. How does cromolyn sodium compare as an active control treatment?". Chest. 109 (4): 945–952. doi:10.1378/chest.109.4.945. PMID 8635375. Archived from the original on 2013-04-14.
  • ^ Carter E (July 31, 2009). "King Pharmaceuticals: Dear Healthcare Professionals" (PDF). Food and Drug Administration. King Pharmaceuticals. Retrieved May 28, 2012.
  • ^ "Intal Inhaler discontinued - MPR". Empr.com. 4 August 2009. Retrieved 2012-05-28.
  • ^ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis". The Cochrane Database of Systematic Reviews. 2015 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMC 10616535. PMID 26028608.
  • ^ Horan RF, Sheffer AL, Austen KF (May 1990). "Cromolyn sodium in the management of systemic mastocytosis". The Journal of Allergy and Clinical Immunology. 85 (5): 852–855. doi:10.1016/0091-6749(90)90067-E. PMID 2110198.
  • ^ Werner's Pathophysiology page 224
  • ^ a b Rang RP, Dale MM, Ritter JM, Keith P (2003). Pharmacology (Fifth ed.). Churchill Livingstone. ISBN 978-0-443-07145-4.
  • ^ Garland LG (1991). "Pharmacology of Prophylactic Anti-Asthma Drugs". Pharmacology of Asthma. Handbook of Experimental Pharmacology. Vol. 98. pp. 261–290. doi:10.1007/978-3-642-75855-3_9. ISBN 978-3-642-75857-7.
  • ^ Heinke S, Szücs G, Norris A, Droogmans G, Nilius B (August 1995). "Inhibition of volume-activated chloride currents in endothelial cells by chromones". British Journal of Pharmacology. 115 (8): 1393–1398. doi:10.1111/j.1476-5381.1995.tb16629.x. PMC 1908889. PMID 8564197.
  • ^ Phua EJ, Lopez X, Ramus J, Goldfine AB (December 2013). "Cromolyn sodium for insulin-induced lipoatrophy: old drug, new use". Diabetes Care. 36 (12): e204–e205. doi:10.2337/dc13-1123. PMC 3836099. PMID 24265375.
  • ^ Yasgur BS (18 December 2013). "A Surprising Option for Managing Insulin-Induced Lipoatrophy".
  • ^ "Alzt-Op1". Alzforum.
  • ^ Penumutchu SR, Chou RH, Yu C (2014-08-01). "Structural insights into calcium-bound S100P and the V domain of the RAGE complex". PLOS ONE. 9 (8): e103947. Bibcode:2014PLoSO...9j3947P. doi:10.1371/journal.pone.0103947. PMC 4118983. PMID 25084534.
  • ^ Penumutchu SR, Chou RH, Yu C (November 2014). "Interaction between S100P and the anti-allergy drug cromolyn". Biochemical and Biophysical Research Communications. 454 (3): 404–409. doi:10.1016/j.bbrc.2014.10.048. PMID 25450399.
  • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Cromoglicic_acid&oldid=1226408013"

    Categories: 
    Mast cell stabilizers
    Enoic acids
    Chromones
    British inventions
    Glycerols
    Orphan drugs
    Hidden categories: 
    CS1 errors: missing periodical
    CS1 errors: missing title
    Articles with short description
    Short description matches Wikidata
    Drugs with non-standard legal status
    Articles with changed DrugBank identifier
    Articles with changed EBI identifier
    ECHA InfoCard ID from Wikidata
    Drugboxes which contain changes to verified fields
    All articles with unsourced statements
    Articles with unsourced statements from March 2024
     



    This page was last edited on 30 May 2024, at 13:06 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki